Shattuck Labs narrows annual loss to $48.8M, gears up for Phase 2 Crohn’s trial
Compartilhar
Shattuck Labs (NASDAQ:STTK) reported a narrowed net loss for fiscal year 2025, driven by a strategic reduction in research and development expenses and a disciplined focus on its lead clinical programs.
